Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1391 ARTÍCULOS , VIENDO DEL 466 AL 480

Trazodone and cognitive performance in Alzheimer disease

Camargos EF, Quintas JL, Louzada LL, Naves JO, Furioso AC, Nóbrega OT.

J Clin Psychopharmacol. 2015 Feb;35(1):88-9. doi: 10.1097/JCP.0000000000000237.

Downsizing of lean body mass is a key determinant of Alzheimer's disease

Ingenbleek Y, Bernstein LH.

J Alzheimers Dis. 2015;44(3):745-54. doi: 10.3233/JAD-141950.

The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial

Nolan JM, Loskutova E, Howard A, Mulcahy R, Moran R, Stack J, Bolger M, Coen RF, Dennison J, Akuffo KO, Owens N, Power R, Thurnham D, Beatty S.

J Alzheimers Dis. 2015;44(4):1157-69. doi: 10.3233/JAD-142265.

Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor

Grossberg GT, Farlow MR, Meng X, Velting DM.

Curr Alzheimer Res. 2015;12(1):53-60. doi: 10.2174/1567205011666141218122835.

New horizons in the management of Alzheimer disease

Morley JE.

J Am Med Dir Assoc. 2015 Jan;16(1):1-5. doi: 10.1016/j.jamda.2014.10.022.

Cognitive-motor intervention in Alzheimer's disease: long-term results from the Maria Wolff trial

Muñiz R, Serra CM, Reisberg B, Rojo JM, Del Ser T, Peña Casanova J, Olazarán J.

J Alzheimers Dis. 2015;45(1):295-304. doi: 10.3233/JAD-142364.

18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease

Bailly M, Ribeiro MJ, Vercouillie J, Hommet C, Gissot V, Camus V, Guilloteau D.

Clin Nucl Med. 2015 Feb;40(2):e111-6. doi: 10.1097/RLU.0000000000000666.

Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease

Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM, Kook KA, Harrington CR.

J Alzheimers Dis. 2015;44(2):705-20. doi: 10.3233/JAD-142874.

Cerebrospinal fluid total prion protein: a potential in vivo marker of cerebral prion pathology

Zetterberg H.

JAMA Neurol. 2015 Mar;72(3):261-3. doi: 10.1001/jamaneurol.2014.4078.

The Link Between Physical Activity and Cognitive Dysfunction in Alzheimer Disease

Phillips C, Baktir MA, Das D, Lin B, Salehi A.

Phys Ther. 2015 Jul;95(7):1046-60. doi: 10.2522/ptj.20140212. Epub 2015 Jan 8.

A disease that strikes close to home

Hickner J.

J Fam Pract. 2015 Jan;64(1):8.

Hemiparkinsonism-hemiatrophy syndrome with Alzheimer's disease

Yang Y, Kwak YT.

Geriatr Gerontol Int. 2015 Jan;15(1):122-3. doi: 10.1111/ggi.12279.

The effectiveness of reality orientation in the treatment of Alzheimer's disease

Camargo CH, Justus FF, Retzlaff G.

Am J Alzheimers Dis Other Demen. 2015 Aug;30(5):527-32. doi: 10.1177/1533317514568004. Epub 2015 Jan 14.

Left temporal lobe epilepsy revealing left posterior cortical atrophy due to Alzheimer's disease

Cretin B, Di Bitonto L, Blanc F, Magnin E.

J Alzheimers Dis. 2015;45(2):521-6. doi: 10.3233/JAD-141953.

A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease

Remington R, Bechtel C, Larsen D, Samar A, Doshanjh L, Fishman P, Luo Y, Smyers K, Page R, Morrell C, Shea TB.

J Alzheimers Dis. 2015;45(2):395-405. doi: 10.3233/JAD-142499.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias